title: Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.
abstract: OBJECTIVE
  To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension.
  
  
  METHODS
  Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months.
  
  
  RESULTS
  No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p> or =0.741). After 6 months, both drugs significantly reduced IOP at every time point (p< or =0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9%) with bimatoprost (n = 76) and 5.7 mm Hg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups.
  
  
  CONCLUSIONS
  Bimatoprost provided greater mean IOP reductions than travoprost.
authors.affiliation: Department of Ophthalmology, Indiana University Medical Center, 702 Rotary Circle, Indianapolis, IN 46202, USA. lcantor@iupui.edu
authors.forename: L B
authors.initials: LB
authors.lastname: Cantor
authors.forename: J
authors.initials: J
authors.lastname: Hoop
authors.forename: L
authors.initials: L
authors.lastname: Morgan
authors.forename: D
authors.initials: D
authors.lastname: Wudunn
authors.forename: Y
authors.initials: Y
authors.lastname: Catoira
mesh_terms: D000368:Aged; D000577:Amides / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000069580:Bimatoprost; D016009:Chi-Square Distribution; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008055:Lipids / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy; D000069557:Travoprost; D016896:Treatment Outcome
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D003008:Cloprostenol; D000069580:Bimatoprost; D000069557:Travoprost